Something different

I'm hoping to post some new findings in the next 3 days. I have some immediate deadlines that need to be addressed before I can go back to having fun :)
I know I have been silent these days, but trying to find a new career (if you have any available let me know :) )

In the mean time please check out these links:
Something different: http://posts.fanbox.com/6l765
Some perfect gifts to give for Christmas!
http://yardsellr.com/yardsale/Zeus-Hens-778835?pap=778835

Sangamo Biosciences .. Treatment for HIV?

Sangamo Biosciences (SGMO)

This is an interesting biopharmaceutical company involved in the development of drugs against HIV at the clinical stage. They have been developing and commercializing the use of zinc finger DNA binding proteins (ZFPs) and modifying them to become nucleases (cut nucleic acids).

Arena Pharmaceuticals and G protein coupled receptors

Arena (ARNA)

This is an interesting biopharmaceutical company. It is focused on developing and commercializing oral drugs that target G-protein-coupled receptors (GPCRs) in the areas of inflammatory, metabolic, cardiovascular, and central nervous system.

Gilead is going for the Gold (in honor of the Olympics :) )

For Fun: Please check out www.wondersofkindle.com Thanks!

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Their primary focus areas include HIV/AIDS, hepatitis B and C, cardiovascular and respiratory conditions. They are a global company with operations in North America, Europe and Asia Pacific.  They have many products as shown below in this table.

Onyx Pharmaceuticals it is all in the black….:)

Onyx Pharmaceuticals has a lot of clinical trials going on and development of drugs in the hopper.

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today in Blood, the medical journal of the American Society of Hematology, has published their results from the 003-A1 Phase 2b trial, a single-arm, multicenter clinical trial evaluating Kyprolis(TM) (carfilzomib) for Injection for the treatment of patients with advanced multiple myeloma, who had received a median of five prior anti-myeloma regimens.

Both sides of the coin for Sanofi

Both sides of the coin for Sanofi

Some interesting recent news in France about Sanofi, which use to be called Sanofi-Aventis, came out today. As we have seen in the past, the people in France like to protest. “Workers at Sanofi (SAN) had a message for politicians at protests in Paris this month: Job cuts by the nation’s biggest drugmaker are crushing morale among researchers and hurting the company’s ability to develop new products (http://www.biospace.com/News/genzyme-corporations-rd-culture-pushes-sanofi/267846) .”

I wonder if it is going to have an effect on what happens to the company? The chief Executive Officer Chris Viehbacher was not persuaded by those arguments.  After purchasing Genzyme Corp. for $20.1 billion last year, the CEO was inspired to refashion Sanofi in the Cambridge, Massachusetts-based company’s image, a project he is pursuing at full bore. Scientists are now organized as hubs, in the hopes that scientists will be more open and share their ideas with one another. In the new headquarters in Paris, he has had coffee bars installed for workers to mingle.  He chose Genzyme executives to run the Boston R&D hub and Sanofi’s U.S. business development. His daughter is even interning at Genzyme. Sounds like he is keeping it all in the family, huh….

Besides the disgruntled employees in France, the FDA has also brought some charges against Sanofi too that they posted on July 12^th on their website. There appears to be mold problems in several of Sanofi’s plants located both in Canada and France.  The drug TheraCys BCG Live is produced in the Canadian plant and because of these issues has created a shortage of the drug. The FDA has requested renovations at the Canadian plant. (http://www.biospace.com/News/fda-to-meet-sanofi-france-execs-over-violations-at/267717)

What does this mean for the stock, SNYNF:OTCQB?

Overall its performance has been up a little over 7% for the year. It doesn’t appear that any analyst is following the stock? OR at least none that is evident on the Scottrade website. The stock has ranged from 62.30 in September of 2011 to 78.45 in July of 2011. Presently the stock is at 74.05, which is just bobbing below the high for the stock. 

If I was going to take a guess, I would say that the stock is going to go down on the news that I have provided above. However, if some new drugs or advancement comes out of Sanofi, then I think the stock will go up a bit. However, from what I see it doesn’t seem like it is going to go up much higher for now.

Check out the chart and the news, and let me know what you think!?

Peregrine Pharmaceuticals is Flying High

For Fun after enjoying my blog, please go to:

http://adf.ly/AltA4 and enjoy a few e-books.

So what is Peregrine Pharmaceutical Inc business?

This company is a clinical-stage biopharmaceutical company that develops and manufactures monoclonal antibodies for the treatment of cancer and viral infections. As of April 30, 2011, the Company had three Phase II clinical programs, including two oncology programs, as well as a hepatitis C virus (HCV) program. Peregrine's pipeline of investigational monoclonal antibodies is based on two technology platforms, including phosphatidylserine (PS)-targeting antibodies and deoxyribonucleic acid (DNA)/histone-targeting antibodies. Bavituximab is its PS-targeting antibody. Cotara is the Company's DNA/histone-targeting antibody-based on its Tumor Necrosis Therapy (TNT) technology platform. Peregrine's wholly owned biomanufacturing subsidiary is Avid Bioservices, Inc., which provides integrated cGMP commercial and clinical manufacturing services for Peregrine and third-party clients (Compliments of Scottrade).

As you can see, this company’s main focus is using antibodies to targeting difficult cancers by either targeting a phospholipid called phosphatidylserine at the cell membrane or by targeting a DNA-histone complex . These are both effective mechanisms for targeting a cancer, especially if it is hard to reach by conventional manners.
More recently, Peregrine provided promising evidence that  bavituximab  improves tumor response and survival trends in a randomized Phase II trial for non-small cell lung cancer (NSCLC).
Additionally, Peregrine announced the start of investigator initiated Phase 1 trial with for up to 18 patients with stage II or III rectal adenocarcinoma with the Eastern Cooperative Oncology Group (ECOG) at Texas Southwestern Medical Center (http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=692072)

So why did I pick this company to blog about? Well, I did a stock screen for companies in healthcare>> Biotechnology and Drugs  that  were over 20% increase in stock price in the last  5 days and checked out the charts of the stock. This stock has had a terrific run for the last few days. The news on PPHM suggests that it will continue to increase; how much more is not known.

Both S&P and Reuters have improved their rating from the negatives to neutral (Rank 4) four days ago. This year is looking good for the Biotechnology stocks.

My 2 cents, as a stock, I would buy it (haha if I had money) at 1.80 is a bargain and watch it to continue its ride up. I would keep an eye on the technicals, because there is sure to be a dip that would be a buying point. Tell me what you think….

Check out the chart below: